Advertisement

Clinical and Translational Oncology

, Volume 19, Issue 1, pp 84–90 | Cite as

Downregulated ECRG4 is correlated with lymph node metastasis and predicts poor outcome for nasopharyngeal carcinoma patients

  • J.-Y. Chen
  • X. Wu
  • C.-Q. Hong
  • J. Chen
  • X.-L. Wei
  • L. Zhou
  • H.-X. Zhang
  • Y.-T. HuangEmail author
  • L. PengEmail author
Research Article

Abstract

Objective

Esophageal cancer-related gene 4 (ECRG4) is a new candidate tumor suppressor gene. In this retrospective study, we evaluated ECRG4 protein expression in patients with nasopharyngeal carcinoma (NPC) under curative treatment and examined its association with pathological features and clinical outcomes as a possible biomarker for diagnosis and prognosis of NPC.

Methods

We enrolled 122 patients with a first diagnosis between January 2001 and December 2003. Tumor tissue and control tissue from biopsies underwent immunohistochemical staining for ECRG4. ECRG4 expression was analyzed by clinicopathological variables. After Kaplan–Meier survival analysis, we used Cox proportional hazards regression to estimate the predictive effect of ECRG4 expression on overall survival.

Results

ECRG4 protein level was lower in NPC than control tissue (P < 0.01). It was inversely related to node status (P < 0.001) and clinical stage (P = 0.027). ECRG4 expression was associated with overall survival, and downregulated ECRG4 expression was an independent prognostic factor of poor survival (hazard ratio = 0.677, 95 % confidence interval 0.463–0.989, P = 0.044).

Conclusions

A significant NPC patients showed downregulated ECRG4 expression, which is correlated with lymph node metastasis. The marker could be an independent prognostic factor for NPC patients. The precise function of ECRG4 in the progression of NPC, especially for lymphatic metastasis, deserves further investigation, which would bring a new target for personalized therapy.

Keywords

Nasopharyngeal carcinoma Esophageal cancer-related gene 4 Lymphatic metastasis Survival analysis Prognostic biomarker 

Notes

Acknowledgments

This work was supported by the Medical Scientific Research Foundation of Guangdong Province, China, A2013392 (L. Peng) A2015383 (YT. Huang), Science and Technology Planning Project of Shantou, Guangdong, China, No.:(2013)244 (L. Zhou). We thank Prof. Kun Lin and Dr. Ku-sheng Wu for critical and helpful advice for the statistical analysis.

Compliance with ethical standards

All procedures performed in studies involving human participants were in accordance with the ethical standards of the Ethics Committee of Shantou University Medical College and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study, written consent was waived, while oral consent from the patients was obtained via telephone and documented by telephone recording.

Conflict of interest

The authors declare that they have no competing interests.

References

  1. 1.
    Cao SM, Simons MJ, Qian CN. The prevalence and prevention of nasopharyngeal carcinoma in China. Chin J Cancer. 2011;30(2):114–9.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Wei WI, Sham JST. Nasopharyngeal carcinoma. Lancet. 2005;365(9476):2041–54.CrossRefPubMedGoogle Scholar
  3. 3.
    Brennan B. Nasopharyngeal carcinoma. Orphanet J Rare Dis. 2006;1:23.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Ng WT, Lee MCH, Hung WM, Choi CW, Lee KC, Chan OSH, et al. Clinical outcomes and patterns of failure after intensity-modulated radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2011;79(2):420–428.Google Scholar
  5. 5.
    Zhang L, Zhao C, Ghimire B, Hong MH, Liu Q, Zhang Y, et al. The role of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma among endemic population: a meta-analysis of the phase III randomized trials. BMC Cancer. 2010;10:558.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Wang J, Shi M, Hsia Y, Luo S, Zhao L, Xu M, et al. Failure patterns and survival in patients with nasopharyngeal carcinoma treated with intensity modulated radiation in Northwest China: a pilot study. Radiat Oncol. 2012;7:2.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Tao Q, Chan AT. Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert Rev Mol Med. 2007;9(12):1–24.CrossRefPubMedGoogle Scholar
  8. 8.
    Su T, Liu H, Lu S. Cloning and identification of cDNA fragments related to human esophageal cancer. Zhonghua zhong liu za zhi (Chin J Oncol). 1998;20(4):254–7.Google Scholar
  9. 9.
    Su T, Liu H, Lu S. Cloning and identification of cDNA fragments related to human esophageal cancer. Zhonghua zhong liu za zhi (Chin J Oncol). 1998;20(4):254–7.Google Scholar
  10. 10.
    Yue CM, Deng DJ, Bi MX, Guo LP, Lu SH. Expression of ECRG4, a novel esophageal cancer-related gene, downregulated by CpG island hypermethylation in human esophageal squamous cell carcinoma. World J Gastroenterol WJG. 2003;9(6):1174–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Gotze S, Feldhaus V, Traska T, Wolter M, Reifenberger G, Tannapfel A, et al. ECRG4 is a candidate tumor suppressor gene frequently hypermethylated in colorectal carcinoma and glioma. BMC Cancer. 2009;9:447.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Wang YB, Ba CF. Promoter methylation of esophageal cancer-related gene 4 in gastric cancer tissue and its clinical significance. Hepatogastroenterology. 2012;59(118):1696–8.PubMedGoogle Scholar
  13. 13.
    Sabatier R, Finetti P, Adelaide J, Guille A, Borg JP, Chaffanet M, et al. Down-regulation of ECRG4, a candidate tumor suppressor gene, in human breast cancer. PLoS One. 2011;6(11):e27656.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Vanaja DK, Ehrich M, Van den Boom D, Cheville JC, Karnes RJ, Tindall DJ, et al. Hypermethylation of genes for diagnosis and risk stratification of prostate cancer. Cancer Invest. 2009;27(5):549–60.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    You Y, Yang W, Qin X, Wang F, Li H, Lin C, et al. ECRG4 acts as a tumor suppressor and as a determinant of chemotherapy resistance in human nasopharyngeal carcinoma. Cell Oncol. 2015;38(3):205–14.CrossRefGoogle Scholar
  16. 16.
    Luo L, Wu J, Xie J, Xia L, Qian X, Cai Z, et al. Downregulated ECRG4 is associated with poor prognosis in renal cell cancer and is regulated by promoter DNA methylation. Tumour Biol J Int Soc Oncodev Biol Med 2015.Google Scholar
  17. 17.
    Mori Y, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A, Kurehara H, et al. Expression of ECRG4 is an independent prognostic factor for poor survival in patients with esophageal squamous cell carcinoma. Oncol Rep. 2007;18(4):981–5.PubMedGoogle Scholar
  18. 18.
    Li LW, Yu XY, Yang Y, Zhang CP, Guo LP, Lu SH. Expression of esophageal cancer related gene 4 (ECRG4), a novel tumor suppressor gene, in esophageal cancer and its inhibitory effect on the tumor growth in vitro and in vivo. Int J Cancer J Int Cancer. 2009;125(7):1505–13.CrossRefGoogle Scholar
  19. 19.
    Liu J, Wei XL, Huang WH, Chen CF, Bai JW, Zhang GJ. Cytoplasmic Skp2 expression is associated with p-Akt1 and predicts poor prognosis in human breast carcinomas. PLoS One. 2012;7(12):e52675.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Lu J, Wen M, Huang Y, He X, Wang Y, Wu Q, et al. C2ORF40 suppresses breast cancer cell proliferation and invasion through modulating expression of M phase cell cycle genes. Epigenetics Off J DNA Methylation Soc. 2013;8(6):571–83.CrossRefGoogle Scholar
  21. 21.
    Xu T, Xiao D, Zhang X. ECRG4 inhibits growth and invasiveness of squamous cell carcinoma of the head and neck in vitro and in vivo. Oncol Lett. 2013;5(6):1921–6.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Mao YP, Xie FY, Liu LZ, Sun Y, Li L, Tang LL, et al. Re-evaluation of 6th edition of AJCC staging system for nasopharyngeal carcinoma and proposed improvement based on magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2009;73(5):1326–34.CrossRefPubMedGoogle Scholar
  23. 23.
    Chen L, Hu C-S, Chen X-Z, Hu G-Q, Cheng Z-B, Sun Y, et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2012;13(2):163–71.CrossRefPubMedGoogle Scholar
  24. 24.
    Ho FC, Tham IW, Earnest A, Lee KM, Lu JJ. Patterns of regional lymph node metastasis of nasopharyngeal carcinoma: a meta-analysis of clinical evidence. BMC Cancer. 2012;12:98.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Li LW, Li YY, Li XY, Zhang CP, Zhou Y, Lu SH. A novel tumor suppressor gene ECRG4 interacts directly with TMPRSS11A (ECRG1) to inhibit cancer cell growth in esophageal carcinoma. BMC Cancer. 2011;11:52.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Matsuzaki J, Torigoe T, Hirohashi Y, Tamura Y, Asanuma H, Nakazawa E, et al. Expression of ECRG4 is associated with lower proliferative potential of esophageal cancer cells. Pathol Int. 2013;63(8):391–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Jia J, Dai S, Sun X, Sang Y, Xu Z, Zhang J, et al. A preliminary study of the effect of ECRG4 overexpression on the proliferation and apoptosis of human laryngeal cancer cells and the underlying mechanisms. Mol Med Rep. 2015;12(4):5058–64.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Porzionato A, Rucinski M, Macchi V, Sarasin G, Malendowicz LK, De Caro R. ECRG4 expression in normal rat tissues: expression study and literature review. Eur J Histochem EJH. 2015;59(2):2458.PubMedGoogle Scholar
  29. 29.
    Baird A, Lee J, Podvin S, Kurabi A, Dang X, Coimbra R, et al. Esophageal cancer-related gene 4 at the interface of injury, inflammation, infection, and malignancy. Gastrointestinal Cancer Targets Ther. 2014;2014(4):131–42.CrossRefGoogle Scholar
  30. 30.
    Karaman S, Detmar M. Mechanisms of lymphatic metastasis. J Clin Investig. 2014;124(3):922–8.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Baylin SB, Ohm JE. Epigenetic gene silencing in cancer—a mechanism for early oncogenic pathway addiction? Nat Rev Cancer. 2006;6(2):107–16.CrossRefPubMedGoogle Scholar
  32. 32.
    Lin DC, Meng X, Hazawa M, Nagata Y, Varela AM, Xu L, et al. The genomic landscape of nasopharyngeal carcinoma. Nat Genet 2014.Google Scholar
  33. 33.
    Bei J-X, Li Y, Jia W-H, Feng B-J, Zhou G, Chen L-Z, et al. A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci. Nat Genet. 2010;42(7):599–603.CrossRefPubMedGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2016

Authors and Affiliations

  • J.-Y. Chen
    • 1
  • X. Wu
    • 1
    • 2
  • C.-Q. Hong
    • 1
  • J. Chen
    • 3
  • X.-L. Wei
    • 2
  • L. Zhou
    • 4
  • H.-X. Zhang
    • 5
  • Y.-T. Huang
    • 5
    Email author
  • L. Peng
    • 6
    • 7
    Email author
  1. 1.Oncological Research LabCancer Hospital of Shantou University Medical CollegeShantouPeople’s Republic of China
  2. 2.Department of PathologyCancer Hospital of Shantou University Medical CollegeShantouPeople’s Republic of China
  3. 3.Department of RadiotherapyCancer Hospital of Shantou University Medical CollegeShantouPeople’s Republic of China
  4. 4.Department of Gynecologic SurgeryCancer Hospital of Shantou University Medical CollegeShantouPeople’s Republic of China
  5. 5.Health Care CenterThe First Affiliated Hospital of Shantou University Medical CollegeShantouPeople’s Republic of China
  6. 6.Clinical LaboratoryCancer Hospital of Shantou University Medical CollegeShantouPeople’s Republic of China
  7. 7.Environmental Medicine and Developmental ToxicityShantou University Medical CollegeShantouPeople’s Republic of China

Personalised recommendations